Politico November 26, 2025
With help from Lauren Gardner
Driving the Day
CMS CELEBRATES — The Trump administration is touting $12 billion in federal savings in Medicare’s second year of drug price negotiations, a figure that health officials say outdoes the program’s first-year savings under President Joe Biden, POLITICO’s David Lim reports.
On the list: The latest negotiations included Pfizer’s breast cancer therapy Ibrance, which 16,000 Medicare Part D beneficiaries used in 2024, and Boehringer Ingelheim’s lung fibrosis treatment Ofev, used by 24,000 people. The government reached a 50 percent discount on both of those drugs compared to their 2024 list prices.
Novo Nordisk’s diabetes and weight-loss drugs yielded negotiated prices of $274 for Ozempic and Rybelsus and $385 for Wegovy for a 30-day...
Today's Sponsors
Today's Sponsor